Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anetumab Ravtansine Combinations in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
NCT03816358Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2019
- Primary completion
- Jan 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of anetumab ravtansine in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose. Started Dec 2019; status: active, not recruiting.
02
Drugs
anetumab ravtansine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03816358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03816358.